Abstract
Colorectal carcinoma is the third most common cancer worldwide. Approximately 20% of patients with colorectal cancer will have metastatic disease at the time of initial diagnosis, and approximately 30% to 50% of patients with primary colon cancer will relapse and die of metastatic cancer. The 5-year survival rate of metastatic colorectal cancer remains disappointing at approximately 10%.Angiogenesis plays a significant role in tumor growth and metastasis in colorectal carcinoma. There are currently 4 US Food and Drug Administration-approved antiangiogenic agents for metastatic colorectal cancer. Bevacizumab is the only antiangiogenic agent approved by the US Food and Drug Administration for first-line treatment of metastatic colorectal cancer. Other antiangiogenic agents include ramucirumab, ziv-aflibercept, and regorafenib. We review the data supporting the use of antiangiogenics in this disease.
MeSH terms
-
Angiogenesis Inhibitors / pharmacology
-
Angiogenesis Inhibitors / therapeutic use*
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Bevacizumab / pharmacology
-
Bevacizumab / therapeutic use
-
Clinical Trials as Topic
-
Colorectal Neoplasms / drug therapy*
-
Colorectal Neoplasms / genetics
-
Colorectal Neoplasms / metabolism
-
Colorectal Neoplasms / pathology*
-
Disease Progression
-
Humans
-
Molecular Targeted Therapy
-
Neovascularization, Pathologic / drug therapy*
-
Neovascularization, Pathologic / genetics
-
Neovascularization, Pathologic / metabolism
-
Retreatment
-
Signal Transduction / drug effects
-
Treatment Outcome
-
Vascular Endothelial Growth Factor A / metabolism
Substances
-
Angiogenesis Inhibitors
-
Antineoplastic Agents
-
Vascular Endothelial Growth Factor A
-
Bevacizumab